Navigation Links
Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
Date:12/14/2009

SAN DIEGO, Dec. 14 /PRNewswire/ -- Pfenex Inc. announced today that it has granted Merck & Co., Inc., through an affiliate, an exclusive worldwide license to Pfenex Expression Technology(TM) Pseudomonas-based recombinant protein expression technology for the production of specific proteins to be used in the development of an undisclosed vaccine candidate.

Under the terms of the agreement Pfenex is eligible to receive approximately $52 million in upfront and milestone payments as well as additional royalty payments on any product sales derived from the agreement. This license represents the second commercial license Merck has been granted to Pfenex Expression Technology(TM).

Merck and Pfenex scientists will collaborate on developing the production strains that will be used to express clinically relevant antigens in support of the preclinical and clinical development of the vaccine candidate. The agreement also includes non-exclusive rights for the production of proteins for diagnostic applications.

"We are pleased to be partnering with Merck," said Bertrand C. Liang, CEO of Pfenex, "This collaboration is a clear example of the strength of the Pfenex Expression Technology being leveraged in the discovery, development and production of novel vaccines."

About Pfenex

Pfenex is a protein production company leveraging the unique and powerful Pfenex Expression Technology(TM) platform based on the micro-organism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

SOURCE Pfenex Inc.


'/>"/>
SOURCE Pfenex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
2. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
3. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
4. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
5. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
6. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
7. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
8. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
11. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... Holdings, Inc. (NYSE: HRC), will present at the Goldman Sachs ... 13, 2017, in Rancho Palos Verdes, California ... officer, is scheduled to present at 3:20 p.m. Pacific Time. ... http://ir.hill-rom.com/events.cfm . A recorded replay will be available one ... 2017. About Hill-Rom ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the ... common cancer among men in the U.S. and the third most common cause of cancer ... that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... York (PRWEB) , ... June 24, 2017 , ... ... the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers ... evenings and weekends so that visits to the dentist fit into their patients’ ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Network today announced the launch of Care Management Alerts and Dashboards, an innovative ... patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near ...
(Date:6/23/2017)... ... 23, 2017 , ... Yesterday, U.S. Senate Republicans revealed details ... and replace the Affordable Care Act (ACA). Like the bill narrowly passed by ... a public health insurance program for low-income children, pregnant women, parents of dependent ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. ... New York, has recently begun offering three new minimally invasive procedures to patients ... procedures and reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, ...
Breaking Medicine News(10 mins):